htl0018318
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02958696)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M1PARTIAL AGONIST
CHRM1 partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- htl0018318
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03592862 | Phase 2 | Sep 30, 2018 | Heptares Therapeutics Limited, Sosei |
| NCT03456349 | Phase 1 | Nov 10, 2017 | Allergan, Heptares Therapeutics Limited |
| NCT03198624 | Phase 1 | May 16, 2017 | Heptares Therapeutics Limited, Richmond Pharmacology |
| NCT02958696 | Phase 1 | Oct 1, 2016 | Hammersmith Medicines Research, Heptares Therapeutics Limited |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Heptares Therapeutics Limited | For profit | 4 | 4 | 2 | 2016 |
| Allergan | For profit | 1 | 0 | 1 | 2017 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2016 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2017 |
| Sosei | For profit | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1